Clinical evaluation of local ocular toxicity in candidate anti-adenoviral agents in vivo

Ophthalmologica

Volumn 223, Issue 4, 2009, Pages 233-238

  Inoue, Hirotoshi ^a   Sonoda, Koh Hei ^b   Ishikawa, Makoto ^c   Kadonosono, Kazuaki ^d   Uchio, Eiichi ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

Adenovirus; Antiviral agent; Cidofovir; Eye drops; Nucleoside reverse transcriptase inhibitor; Stavudine; Zalcitabine

Indexed keywords

CIDOFOVIR; EYE DROPS; STAVUDINE; ZALCITABINE;

ADENOVIRUS; ANIMAL EXPERIMENT; ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; EYE TOXICITY; EYELID ERYTHEMA; FEMALE; HISTOPATHOLOGY; LACRIMAL DUCT; LACRIMAL DUCT OCCLUSION; NONHUMAN; RABBIT; SCORING SYSTEM; VIRAL CONJUNCTIVITIS;

ADENOVIRIDAE INFECTIONS; ANIMALS; ANTIVIRAL AGENTS; CONJUNCTIVA; CONJUNCTIVITIS, VIRAL; CYTOSINE; DISEASE MODELS, ANIMAL; EYELIDS; FEMALE; LACRIMAL APPARATUS; OPHTHALMIC SOLUTIONS; PHOSPHONIC ACIDS; RABBITS;

EID: 61349200179     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000205585     Document Type: Article

References (23)

1. De Jong JC, Wermenbol AG, Verweij-Uijter-waal MW, Slaterus, Wertheim-Van Dillen P, Van Doornum GJ, Khoo SH, Hierholzer JC: Adenoviruses from human immunodeficiency virus-infected individuals, including two strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol 1999;37:3940-3945.
2. Schrauder A, Altmann D, Laude G, Claus H, Wegner K, Köhler R, Habicht-Thomas H, Krause G: Epidemic conjunctivitis in Germany, 2004. Eur Surveill 2006;11:185-187.
3. Asencio-Durán M, Romero-Martín R, Gar-cía- Martínez JR, Peralta-Calvo JM, Pérez-Blanco V, García-Caballero J, Malo-Martínez C: Nosocomial outbreak of epidemic keratoconjunctivitis in a neonatal intensive care unit. Arch Soc Esp Oftalmol 2007; 82: 73-80.
4. De Oliveira B, Stevenson D, LaBree L, McDonnel PJ, Trousdale MD: Evaluation of cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. Antiviral Res 1996;31:165-172.
5. Gordon YJ, Romanowski EG, Araullo-Cruz TP, Seaberg L, Erzurum S, Tolman R, De Clercq E: Inhibitory effect of ( S )-HPMPC, ( S )-HPMPA, and 2′-nor-cyclic-GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antiviral Res 1991;16:11-16.
6. Gordon YJ, Romanowski EG, Araullo-Cruz TP: Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model. Invest Ophthalmol Vis Sci 1994;35:4135-4143.
7. Romanowski EG, Gordon YJ: Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci 2000;41:460-463.
8. Mentel R, Kinder M, Wegner U, Janta-Lipin-ski M, Matthes E: Inhibitory activity of 3′-fluoro-2'-deoxythymidine and related nucleoside analogues against adenovirus in vitro. Antiviral Res 1997;34:113-119.
9. Mentel R, Wegner U: Evaluation of the efficacy of 2′,3′- dideoxycydine against adenovirus infection in a mouse pneumonia model. Antiviral Res 2000;47:79-87.
10. Hillenkamp J, Reinhard T, Ross RS, Bohring-er D, Cartsburg O, Roggendorf M, De Clercq E, Godehardt E, Sundmacher R: The effects of cidofovir 1% with and without cyclosporin A 1% as a topical treatment of acute adenoviral keratoconjunctivitis: a controlled clinical pilot study. Ophthalmology 2002;109:845-850.
11. Bordigoni P, Carret AS, Venard V Witz F, Le Faou A: Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001;32:1290-1297.
12. Gavin PJ, Katz BZ: Intravenous ribavirin treatment for severe adenovirus disease in immunocompromised children. Pediatrics 2002;110:1-8.
13. Morfin F, Dupuis-Girod S, Mundweiler S, Falcon D, Carrington D, Sedlacek P, Bierings M, Cetkovsky P, Kroes AC, van Tol MJ, Thouvenot D: In vitro susceptibility of adenovirus to antiviral drugs is species-dependent. Antiviral Ther 2005;10:225-229.
14. Uchio E, Fuchigami A, Kadonosono K, Hayashi A, Ishiko H, Aoki K, Ohno S: Antiadenoviral effect of anti-HIV agents in vitro in serotypes inducing keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 2007; 245:1319-1325.
15. Tost F, Bruder R, Clemens S: Clinical diagnosis of chronic canaliculitis by 20-MHz ultrasound. Ophthalmologica 2000;214:433-436.
16. Mitsuya H, Jarrett RF, Matsukura M, Di Marzo Veronese F, DeVico AL, Sarngad-haran MG, Johns DG, Reitz MS, Broder S: Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro. Proc Natl Acad Sci USA 1987; 84:2033-2037.
17. 3 against adenovirus in vitro. Antiviral Res 2001;52:281-288.
18. Xiang J, Fang X, Li X: Transbuccal delivery of 2′,3′- dideoxycytidine: in vitro permana-tion study and histological investigation. Int J Pharm 2002;231:57-66.
19. Kaul S, Dandekar KA, Schilling BE, Barbhaiya RH: Toxicokinetics of 2′,3′-didehydro3′-deoxythymidine, stavudine (D4T). Drug Metab Dispos 1999; 27: 1-12.
20. Tost FH, Darman J, Clemens S: 20-MHz ultrasound and its value in imaging of lacrimal plugs. Ophthalmologica 2004;218:14-19.
21. Hurwitz JJ, Pavlin CJ, Rhemtulla E: Identification of retained intracanalicular plugs with ultrasound biomicroscopy. Can J Ophthalmol 2004;39:533-537.
22. Romanowski EG, Araullo-Cruz T, Gordon YJ: Multiple adenoviral serotypes demonstrate host range extension in the New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci 1998;39:532-536.
23. Kaneko H, Mori S, Suzuki O, Iida T, Shigeta S, Abe M, Ohno S, Aoki K, Suzutani T: The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir. Antiviral Res 2004;61:63-66.